Atazanavir Sulfate (Reyataz)

An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.

Also Known As:

Reyataz; 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester; Atazanavir; BMS 232632; BMS-232632; BMS-232632-05; BMS232632; CGP 73547; CGP 75136; CGP 75176; CGP 75355; CGP-73547; CGP-75136; CGP-75176; CGP-75355; CGP75136; CGP75176; CGP75355; 232632, BMS; BMS 232632 05; BMS23263205; CGP73547

Networked: 477 relevant articles (20 outcomes, 83 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	McComsey, Grace A: 10 articles (01/2022 - 06/2011)
2.	Daar, Eric S: 10 articles (01/2019 - 12/2009)
3.	Morse, Gene D: 10 articles (01/2019 - 03/2006)
4.	Sax, Paul E: 10 articles (01/2019 - 12/2009)
5.	McGrath, Donnie: 10 articles (04/2014 - 02/2008)
6.	Haas, David W: 8 articles (01/2020 - 11/2004)
7.	Fischl, Margaret A: 8 articles (01/2019 - 03/2007)
8.	Tierney, Camlin: 8 articles (01/2019 - 12/2009)
9.	Lazzarin, Adriano: 8 articles (12/2018 - 07/2004)
10.	Brown, Todd T: 7 articles (01/2022 - 07/2012)

Related Diseases

1.	Hyperlipidemias (Hyperlipidemia) 08/01/2011 - "Switch to atazanavir-containing regimens that were well tolerated resulted in significant improvement of hyperlipidemia and maintenance of clinical, immunologic, and virologic responses to CART." 08/01/2011 - "This study aimed to evaluate the clinical, virologic, and immunologic outcomes in HIV-infected patients with hyperlipidemia whose CART was switched to atazanavir-containing antiretroviral regimens. " 09/01/2013 - "The factors associated with a prolonged QTc were hyperlipidemia (OR 3.7, 95% CI: 1.3-10.3; p=0.01) and diastolic dysfunction (OR 6.7, 95% CI: 2.4-18.3; p=0.0001), while the use of atazanavir was associated with a lower likelihood of having a prolonged QTc (OR 0.11, 95% CI: 0.02-0.5; p=0.008). " 08/01/2011 - "In this 48-week prospective, observational study that was conducted at designated hospitals for HIV care in Taiwan, HIV-infected patients aged 18 years or older who had developed hyperlipidemia after receiving CART that did not contain atazanavir were enrolled. " 11/01/2009 - "Atazanavir (ATV) has been successfully used in HIV patients with severe hyperlipidemia (HL); however, little is known about the pharmacokinetics of ATV in HL. "
2.	Infections 06/01/2018 - "A 40-year-old man with no comorbidities, except human immunodeficiency virus 1 infection, presented with palpitations 3 days after an overdose of 150 caps of atazanavir, with suicidal intent. " 01/01/2016 - "His past history included human immunodeficiency virus infection, which had been treated with atazanavir for 7 years. " 08/01/2012 - "In our patients with mild impairment of hepatic function caused by HCV infection, atazanavir C (trough) was comparable in HIV-infected and HIV/HCV-co-infected patients." 04/01/2012 - "Atazanavir: in pediatric patients with HIV-1 infection." 05/01/2010 - "Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection."
3.	Acquired Immunodeficiency Syndrome (AIDS) 01/01/2018 - "Apparent oral clearance (CL/F) of atazanavir was estimated from plasma samples collected from participants in AIDS Clinical Trials Group Study A5202. " 01/01/2016 - "Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)." 12/01/2014 - "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." 01/01/2023 - "Atazanavir sulphate is a drug used for treatment of AIDS in which the patients are infected with HIV. " 01/01/2007 - "Over 10 years, patients who started on atazanavir had 30 additional AIDS events per 100 patients. "
4.	HIV Infections (HIV Infection) 07/01/2004 - "Data on atazanavir for the treatment of HIV infection are limited to several phase II and III trials, one of which is still ongoing. " 01/01/2018 - "Thus, we investigated the chronic inflammatory state associated with HIV infection as a source of pharmacokinetic variability of atazanavir. " 01/01/2017 - "Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?" 02/01/2015 - "Atazanavir (ATV) is an attractive option for the treatment of Pediatric HIV infection, based on once-daily dosing and the availability of a formulation appropriate for younger children. " 06/18/2012 - "Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use."
5.	Dyslipidemias (Dyslipidemia) 07/01/2004 - "Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials." 08/15/2004 - "Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia. " 04/01/2005 - "However, newer PIs such as atazanavir may result in less insulin resistance and dyslipidemia and, as part of a HAART regimen, use of atazanavir may reduce the metabolic complications associated with HAART." 01/01/2016 - "Dyslipidemia as a risk factor of cardiovascular disease is common especially in HIV-infected patients who are using protease inhibitors (PIs) including atazanavir. " 11/27/2010 - "This observational cohort was designed to investigate the cardiovascular impact of boosted atazanavir (ATV/r), a protease inhibitor that does not provide major dyslipidemia or insulin resistance. "

Related Drugs and Biologics

1.	Ritonavir (Norvir)
2.	Lipids
3.	Lopinavir
4.	Protease Inhibitors (Protease Inhibitor)
5.	Tenofovir (Viread)
6.	Emtricitabine (Emtriva)
7.	Darunavir (Prezista)
8.	efavirenz (Sustiva)
9.	lamivudine drug combination abacavir
10.	Bilirubin

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Tapering
3.	Highly Active Antiretroviral Therapy (HAART)
4.	Art Therapy
5.	Female Contraceptive Devices (Vaginal Ring)